Skip navigation

Strengthen Program Compliance and Integrity in an Evolving Regulatory Landscape

August 22-23, 2017
  • Alexandria, VA

Final Rule Update New CMS Proposed Rule on Medicare Part B Reimbursement and 340B
On July 13, 2017, CMS issued a proposed rule on Outpatient Medicare Payment Systems that would change the Medicare Part B reimbursement rate for drugs obtained through 340B.

With evolving regulations impacting 340B programs, pharmaceutical companies are faced with uncertainty on how to strengthen program compliance and integrity. CBI’s 340B Manufacturer Summit breaks down and clarifies the impending regulations, provides strategies to develop comprehensive self-disclosure response and auditing processes,
and establish best practices to collaborate with contract
pharmacies and covered entities.

NEW! Update on State Efforts to Exclude 340B Drugs from Medicaid Managed Care Rebates

Adam Freeman
Team Leader, U.S. Department of
Health and Human Services
Office of Inspector General

CLE and CPE
Credits Available! Pending Approval

Critical Updates, Interactive Discussions and Valuable Takeaways:

  • Develop proactive techniques to improve new policy adoption and program compliance
  • Determine impact of the Mega-Guidance withdrawal on diversion risk
  • Review manufacturer comments on HRSA’s Final Rule regarding manufacturer ceiling prices and civil monetary penalties
  • Reduce duplicate discount loss potential by working with intermediaries to conduct good faith dispute resolution
  • Evaluate the evolving specialty bio/pharma landscape and discuss changes in decision-making autonomy, payment methodology and delivery system structure
  • Discuss options to increase visibility into contract pharmacies and understand how claims adjudication has occurred
  • Uncover best practices to respond to covered entities and initiate good faith financial remediation

PLUS! Hear Insights from the Industry’s First 340B Closed-Door Collaboration Forum

Previous Attendee Acclaim:

The lineup of speakers for the program were top notch.
The meeting was timely and gave plenty of opportunities
to network with attendees.

President, Apexus

As always, CBI delivered a conference filled with quality content and subject matter experts in the government programs field.

Director, Contracts and Pricing, Acorda Therapeutics, Inc.

The CBI Conference was outstanding — very informative and timely topics covering the hot industry trends.
Very worthwhile event to attend.

Executive Director, Finance,
Customer Contract Management and Government Pricing, Merck

The program was beyond a value-add. The mix of knowledge with the presenters provided something for every participant.

Manager, Strategic Contracting, Johnson & Johnson

August 22-23, 2017 Hilton Old Town Alexandria, VA

340B Manufacturer Summit

Strengthen Program Compliance and Integrity in an Evolving Regulatory Landscape

Final Rule Update New CMS Proposed Rule on Medicare Part B Reimbursement and 340B
On July 13, 2017, CMS issued a proposed rule on Outpatient Medicare Payment Systems that would change the Medicare Part B reimbursement rate for drugs obtained through 340B.

With evolving regulations impacting 340B programs, pharmaceutical companies are faced with uncertainty on how to strengthen program compliance and integrity. CBI’s 340B Manufacturer Summit breaks down and clarifies the impending regulations, provides strategies to develop comprehensive self-disclosure response and auditing processes,
and establish best practices to collaborate with contract
pharmacies and covered entities.

NEW! Update on State Efforts to Exclude 340B Drugs from Medicaid Managed Care Rebates

Adam Freeman
Team Leader, U.S. Department of
Health and Human Services
Office of Inspector General

CLE and CPE
Credits Available! Pending Approval

Critical Updates, Interactive Discussions and Valuable Takeaways:

  • Develop proactive techniques to improve new policy adoption and program compliance
  • Determine impact of the Mega-Guidance withdrawal on diversion risk
  • Review manufacturer comments on HRSA’s Final Rule regarding manufacturer ceiling prices and civil monetary penalties
  • Reduce duplicate discount loss potential by working with intermediaries to conduct good faith dispute resolution
  • Evaluate the evolving specialty bio/pharma landscape and discuss changes in decision-making autonomy, payment methodology and delivery system structure
  • Discuss options to increase visibility into contract pharmacies and understand how claims adjudication has occurred
  • Uncover best practices to respond to covered entities and initiate good faith financial remediation

PLUS! Hear Insights from the Industry’s First 340B Closed-Door Collaboration Forum

Previous Attendee Acclaim:

The lineup of speakers for the program were top notch.
The meeting was timely and gave plenty of opportunities
to network with attendees.

President, Apexus

As always, CBI delivered a conference filled with quality content and subject matter experts in the government programs field.

Director, Contracts and Pricing, Acorda Therapeutics, Inc.

The CBI Conference was outstanding — very informative and timely topics covering the hot industry trends.
Very worthwhile event to attend.

Executive Director, Finance,
Customer Contract Management and Government Pricing, Merck

The program was beyond a value-add. The mix of knowledge with the presenters provided something for every participant.

Manager, Strategic Contracting, Johnson & Johnson

August 22-23, 2017 Hilton Old Town Alexandria, VA